Amgen announces evolocumab (AMG 145) results from first 52-week study of a PCSK9 inhibitor to reduce LDL cholesterol
20 November 2013 | By Amgen
Data presented at American Heart Association Scientific sessions 2013 and simultaneously published in circulation...